Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 16/20 | 0.50 |
| ▸ | TAF1 | P21675 | 4/20 | 0.50 |
| ▸ | PLK1 | P53350 | 12/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 8/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | FES | P07332 | 2/20 | 0.42 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755686 | 0.81 | BRD4 (0.64) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL10098784 | 0.79 | PLK1 (0.61) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL617429 | 0.79 | PLK1 (0.61) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL21755699 | 0.76 | PLK1 (0.66) | MAPK7BRD4PLK1PTK2PLK3 | |
| SCHEMBL21755682 | 0.74 | PLK1 (0.51) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL4981862 | 0.74 | PLK1 (0.55) | MAPK7BRD4PLK1BRDTRAD52 | |
| SCHEMBL1202930 | 0.73 | BRD4 (0.79) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL21755701 | 0.71 | PLK1 (0.66) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL19105507 | 0.70 | PLK1 (0.51) | MAPK7BRD4TAF1PLK1BRDT | |
| SCHEMBL2395758 | 0.70 | PLK1 (0.54) | BRD4PLK1BRDTRAD52ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | MAPK7 253/4885BRD4 614/4885TAF1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.